

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/124259/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Frew, J.W., Navrazhina, K., Byrd, A.S., Garg, A., Ingram, J.R. ORCID: <https://orcid.org/0000-0002-5257-1142>, Kirby, J.S., Lowes, M.A., Naik, H., Piguet, V. and Prens, E.P. 2019. Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies. British Journal of Dermatology 181 (6) 10.1111/bjd.18309 file

Publishers page: <http://dx.doi.org/10.1111/bjd.18309>
<<http://dx.doi.org/10.1111/bjd.18309>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Defining Lesional, Perilesional and Unaffected Skin in Hidradenitis Suppurativa:
Proposed Recommendations for Clinical Trials and Translational Research Studies

JW Frew¹, K Navrazhina^{1,2}, A Byrd³, A Garg⁴, JR Ingram⁵, JS Kirby⁶, MA Lowes¹, H Naik⁷, V
Piguet^{8,9}, EP Prens¹⁰

¹Laboratory of Investigative Dermatology, The Rockefeller University, NY, USA

²Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, Weill Cornell
University, NY, USA

³Department of Dermatology, Howard University, Washington DC, USA

⁴Department of Dermatology, Hofstra Northwell School of Medicine, New Hyde Park, NY, USA

⁵Institute of Infection & Immunity, Cardiff University, University Hospital of Wales, Cardiff, UK

⁶Department of Dermatology, Penn State Hershey Medical Center, Hershey, PA, USA.

⁷Department of Dermatology, University of California, San Francisco, USA

⁸Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada

⁹Division of Dermatology, Dept of Medicine, University of Toronto, Toronto, Ontario, Canada

¹⁰Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands

Word Count: 631

Figure Count: 1

Corresponding Author:

John W Frew

Laboratory of Investigative Dermatology,

The Rockefeller University

1230 York Avenue

New York, NY, United States of America

Ph: +1-212-327-7153

Fax: +1-212-327-8232

Email: jfrew@rockefeller.edu

Key Words: Hidradenitis Suppurativa, Biopsy, Clinical Trial, Guidelines, Lesion, Definition

Main Text:

Hidradenitis suppurativa (HS) is a chronic, recurring inflammatory skin condition for which the pathogenesis is not completely elucidated¹. With the increase in HS-related research comes the need to enhance reproducibility, quality, accuracy and reproducibility of scientific methods. Unlike other inflammatory dermatoses such as psoriasis or atopic dermatitis, HS lesions are morphologically diverse and include nodules, abscesses, tunnels and fibrosis in various permutations and combinations admixed in the same anatomical region¹. This makes general definitions as 'lesional' and 'non-lesional' insufficient for HS-related investigations. A definition for non-lesional skin is lacking. Accurate assessment of the pathophysiologic changes in HS lesions (and the response to therapeutics) requires standardized definitions of lesional, perilesional and unaffected skin biopsies. This is especially pertinent given the well-characterized compartmentalization of cytokines in HS², indicating that serum inflammatory markers may not accurately reflect the inflammatory milieu of lesional HS tissue. An additional complicating factor is the unique inflammatory environment of healthy axillae, groin and submammary folds with an increased IL-17 and innate immune signature³, which makes it crucial to ensure that unaffected skin samples are taken from a site that ensures an accurate comparison. For control specimens, or samples from healthy volunteers, the use of surgical discard from abdominoplasty is problematic given the unique immunological milieu of apocrine-rich (axillary, inguinal, submammary) skin³. The use of region-matched control tissue is vital to avoid overestimation of the relative change of Th17 and other innate immune markers. Ideally, healthy control skin should also be matched for other criteria such as age, gender, and ethnicity.

Examination of the existing literature⁴ pertaining to inflammatory mediators in HS identified two high-quality studies with *a priori* definitions of biopsy sites^{5,6}. Lesional skin was defined as the edge of an inflammatory lesion, perilesional as normal-appearing skin 2cm away from the inflammatory lesion, and unaffected skin as normal-appearing skin ≥ 10 cm distant. An important caveat is that the reference lesion in these studies requires a priori definition. For the majority of published studies this was an inflammatory nodule. Biopsies for tunnels may require deeper full-dermal tissue sampling. It is known that histologically fibrotic tissue attenuates the levels of inflammatory mediators compared with non-fibrotic tissue, and the invasive proliferative gelatinous mass (IPGM) of HS tunnels has a specific cytokine signature distinct from lesional tissue⁷. Therefore, classifying the reference lesion (nodule, tunnel, hypertrophic scar) is crucial for comparison across studies. The presence of dermal tunnels may introduce unintended pathology which can be difficult to appreciate clinically, and hence ultrasound is a useful non-invasive assessment tool to identify dermal tunnels and deep abscesses in order to avoid inadvertent biopsy of a lesion in place of a control sample.

In the context of clinical trials, assessment of lesional tissue is often an exploratory endpoint⁸ given the lack of biomarkers in HS. While the data are not considered a primary or secondary endpoint, they do contribute to the existing knowledge of pathophysiology of disease.

Therefore, based upon the existing literature (and the authors' combined experience) we propose the following recommendations: (1) samples should be obtained from three sites: lesional, perilesional, and unaffected skin; (2) the definitions of lesional, perilesional and

unaffected skin as presented in Figure 1; (3) the anatomic region of the lesion should be recorded; (4) the lesion morphology should be classified (e.g. inflammatory nodule, abscess, tunnel, etc.); and (5) unaffected skin of HS patients and control (taken from healthy volunteers) samples, should be region matched to lesional and perilesional samples (ie. Within the same anatomical region). In the absence of clear standards for HS tissue sampling, these recommendations seek to begin this process. Consensus among stakeholders is needed on a valid and reliable approach to tissue sampling, so that these strategies can be implemented in future studies. The next step is to create a coherent consensus and this work is underway.

References:

- 1) Saunte DML, Jemec GBJ Hidradenitis Suppurativa: Advances in Diagnosis and Treatment JAMA 2017;318(2):2019-2032
- 2) Kanni T Tzanertakou V, Savva A et al Compartmentalized Cytokine Responses in Hidradenitis Suppurativa PLoS One 2015;10(6):e0130522
- 3) Jenei A, Dajnoki Z, Medgyesi B, Gaspar K et al Apocrine Gland Rich Skin Has a Non-Inflammatory IL-17-Related Immune Mileu, that Turns to Inflammatory IL-17 Mediated Disease in Hidradenitis Suppurativa. J Invest Dermatol 2019;139(4):964-968
- 4) Frew JW, Hawkes JE, Krueger JG A Systematic Review and critical evaluation of inflammatory cytokine associations in Hidradenitis Suppurativa F1000Res 2018;13;7:1930

- 5) Moran B, Sweeney CM, Hughes R, Malara A, Kirthi S et al Hidradenitis Suppurativa is Characterized by Dysregulation of the Th17:Treg cell axis, which is corrected by anti TNF therapy J Invest Dermatol 2017;137(11):2389-2395
- 6) Kelly G, Hughes R, McGarry T, van den Born M, Adamzik K, et al Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa Br J Dermatol 2015;173(6):1431-1439
- 7) Kidacki M, Cong Z, Flamm A, Helm K, et al Invasive Proliferative gelatinous mass of hidradenitis suppurativa contains distinct inflammatory components. Br J Dermatol 2018. Doi: 10.1111/bjd.17541
- 8) Kimball AB, Okun MM, Williams DA, Gottlieb AB et al Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa N Engl J Med 2016;375:422-434

Figure Legends:

Figure 1: Biopsy Definition Recommendations for Hidradenitis Suppurativa